SCHEMBL6495346

SCHEMBL6495346

Fc1ccc(F)c(CNc2ccc3[nH]c4ccccc4c3c2)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
KMT2A Q03164 2/20 0.45
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
KIF11 P52732 3/20 0.43
MAPT P10636 2/20 0.41
GAA P10253 2/20 0.41
AHR P35869 1/20 0.41
NPY5R Q15761 1/20 0.39
P2RY12 Q9H244 2/20 0.39
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492565 0.89 KMT2A (0.47) KDM4EKMT2AMTNR1AMTNR1BKIF11
SCHEMBL6496788 0.85 GAA (0.46) KDM4EKMT2AMTNR1AMTNR1BKIF11
SCHEMBL6491702 0.80 GAA (0.49) KDM4EKMT2AMTNR1AMTNR1BKIF11
SCHEMBL6529029 0.78 MAPT (0.41) KDM4EKMT2AMAPTGAAALDH1A1
SCHEMBL6483228 0.76 MAPT (0.51) KDM4EKMT2AMTNR1AMTNR1BKIF11
SCHEMBL6482625 0.76 CYP1A2 (0.40) KDM4EKMT2AMAPTAHRNPY5R
SCHEMBL9231467 0.73 KDM4E (0.58) KDM4EKMT2AMTNR1AMTNR1BKIF11
SCHEMBL6492248 0.72 KMT2A (0.47) KDM4EKMT2AMTNR1AMTNR1BKIF11
SCHEMBL6493014 0.72 KMT2A (0.50) KDM4EKMT2AMTNR1AMTNR1BKIF11
SCHEMBL6497640 0.72 KMT2A (0.49) KDM4EKMT2AMTNR1AMTNR1BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 KDM4E 1279/4885KMT2A 412/4885MTNR1A 1008/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 KDM4E 1476/4885KMT2A 770/4885MTNR1A 569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.